课题基金 / 基金详情

ACTG 382--PHASE I/II, OPEN LABEL, AUC CONTROLLED STUDY DMP 266

ACTG 382--PHASE I/II, OPEN LABEL, AUC CONTROLLED STUDY DMP 266
ACTG 382--I/II 期、开放标签、AUC 对照研究 DMP 266
批准号:
6441962
负责人:
Kenneth McIntosh
金额:
$2.88万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-12-01 至 2001-11-30

项目摘要

项目成果

Kenneth McIntosh的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ACTG 382 is an open-label, AUC-controlled, multicenter study. All subjects will receive DMP 266 and nelfinavir. DMP 266 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) which, in vitro, inhibits HIV production from infected cells. Dosage guidelines for children will be developed following analysis of the plasma level data and the DMP 266 dose used to obtain the target AUC. The primary objectives of the study are 1) to determine the dosing regimen of DMP 266 in combination with nelfinavir in children; and 2) to study the safety profile of DMP 266 in combination with nelfinavir in children.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PACTG 1038: HIGH DOSE LOPINAVIR/RITONAVIR W/ OR W/OUT SAQUINAVIR IN HIV
  • 批准号:
    7607270
  • 项目类别:
  • 资助金额:
    $1.3万
  • 财政年份:
    2007
  • 负责人:
    Kenneth McIntosh
  • 依托单位:
PACTG 1038:PHASE I/II HIGH DOSE LOPINAVIR/RITONAVIR WITH OR WITHOUT SAQUINAVIR I
  • 批准号:
    7380759
  • 项目类别:
  • 资助金额:
    $13.6万
  • 财政年份:
    2006
  • 负责人:
    Kenneth McIntosh
  • 依托单位:
A COLLABORATIVE STUDY OF VERTICAL TRANSMISSION OF HIV (WITS IV)
  • 批准号:
    6975158
  • 项目类别:
  • 资助金额:
    $0.04万
  • 财政年份:
    2004
  • 负责人:
    Kenneth McIntosh
  • 依托单位:
PACTG-1024 Eval. of the Immunogenicity of pneumococcal conjugate vaccine & rout.
  • 批准号:
    6975147
  • 项目类别:
  • 资助金额:
    $0.21万
  • 财政年份:
    2004
  • 负责人:
    Kenneth McIntosh
  • 依托单位:
海外基金